LOXL2 promotes aggrecan and gender-specific anabolic differences to TMJ cartilage

In the United States, 5–12% of adults have at least one symptom of temporomandibular joint (TMJ) disorders, including TMJ osteoarthritis (TMJ-OA). However, there is no chondroprotective agent that is approved for clinical application. We showed that LOXL2 is elevated in the regenerative response dur...

Descripción completa

Detalles Bibliográficos
Autores principales: Tashkandi, Mustafa M., Alsaqer, Saqer F., Alhousami, Thabet, Ali, Faiza, Wu, Yu-Chiao, Shin, Jennifer, Mehra, Pushkar, Wolford, Larry M., Gerstenfeld, Louis C., Goldring, Mary B., Bais, Manish V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7678826/
https://www.ncbi.nlm.nih.gov/pubmed/33214607
http://dx.doi.org/10.1038/s41598-020-77178-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7678826/
https://www.ncbi.nlm.nih.gov/pubmed/33214607
http://dx.doi.org/10.1038/s41598-020-77178-9

Ejemplares similares